Assessing the Beneficial Impact of a Patient Support Program in Secukinumab-Treated Patients with Psoriasis in Italy
Giuseppe Argenziano,1,* Paolo Amerio,2 Maria Grazia Aragone,3 Ginevra Baggini,4 Manuela Baldari,5 Gianpiero Castelli,6 Simmaco Coppola,7 Antonio Costanzo,8,9 Rocco De Pasquale,10 Maria Concetta Fargnoli,11 Caterina Foti,12 Claudia Giofrè,13 Serena Lembo,14 Claudia Leporati,15,16 Francesco...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/c4a24d587ebb4a109ffacd9b7187f80d |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:c4a24d587ebb4a109ffacd9b7187f80d |
|---|---|
| record_format |
dspace |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
dermatology psolife care program quality of life treatment adherence Medicine (General) R5-920 |
| spellingShingle |
dermatology psolife care program quality of life treatment adherence Medicine (General) R5-920 Argenziano G Amerio P Aragone MG Baggini G Baldari M Castelli G Coppola S Costanzo A De Pasquale R Fargnoli MC Foti C Giofrè C Lembo S Leporati C Loconsole F Malara G Peris K Richetta AG Savoia P Tiberio R Travaglini M Uzzauto MT Bianchi L Assessing the Beneficial Impact of a Patient Support Program in Secukinumab-Treated Patients with Psoriasis in Italy |
| description |
Giuseppe Argenziano,1,* Paolo Amerio,2 Maria Grazia Aragone,3 Ginevra Baggini,4 Manuela Baldari,5 Gianpiero Castelli,6 Simmaco Coppola,7 Antonio Costanzo,8,9 Rocco De Pasquale,10 Maria Concetta Fargnoli,11 Caterina Foti,12 Claudia Giofrè,13 Serena Lembo,14 Claudia Leporati,15,16 Francesco Loconsole,17 Giovanna Malara,18 Ketty Peris,19,20 Antonio Giovanni Richetta,21 Paola Savoia,22 Rossana Tiberio,23 Massimo Travaglini,24 Maria Teresa Uzzauto,25 Luca Bianchi26,* 1Dermatology Unit, University of Campania, Naples, Italy; 2Department of Medicine and Aging Science and Dermatologic Clinic, University “G. d’Annunzio”, Chieti-Pescara, Chieti, Italy; 3ASL AL, Alessandria, Italy; 4Osp. Civile di Varzi, Pavia, Italy; 5ASL4 Liguria, Genova, Italy; 6UOSD of Dermatology, Ospedale Umberto I°, Siracusa, Italy; 7IQVIA, Rome, Italy; 8Department of Biomedical Sciences, Humanitas University, Milano, Italy; 9Skin Pathology Laboratory, Humanitas Research Hospital IRCCS, Milano, Italy; 10UOC Dermatologia, AOU Policlinico “G. Rodolico – San Marco”, Catania, Italy; 11Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy; 12Department of Biomedical Science and Human Oncology, Dermatological Clinic, University of Bari, Bari, Italy; 13U.O.C. Dermatologia, A.O. Papardo, Messina, Italy; 14Dipartimento di Medicina, Chirurgia e Odontoiatria Scuola Medica Salernitana, University of Salerno, Fisciano, Italy; 15Dermatology Unit, ASL AL Casale Monferrato, Alessandria, Italy; 16Dermatology Unit, ASL TO4 Ivrea, Torino, Italy; 17Department of Dermatology, University of Bari, Bari, Italy; 18UOC of Dermatology, Grande Ospedale Metropolitano “BMM”, Reggio Calabria, Italy; 19Institute of Dermatology, Catholic University, Rome, Italy; 20Dermatology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; 21Dipartimento di Scienze Cliniche Internistiche e Cardiovascolari Policlinico Umberto I University of Rome “La Sapienza”, Rome, Italy; 22Department of Health Science, Università del Piemonte Orientale, Novara, Italy; 23SCDU Dermatologia, AOU Maggiore della Carità, Novara, Italy; 24U.O.S.D. dermatologica - centro per la cura della psoriasi, Ospedale Perrino, Brindisi, Italy; 25U.O.C. Dermatologia, ASL Salerno, Ospedale “A:Tortora”-Pagani, Salerno, Italy; 26Dermatology Unit, Tor Vergata University Hospital, Rome, Italy*These authors contributed equally to this workCorrespondence: Giuseppe ArgenzianoDermatology Unit, University of Campania “Luigi Vanvitelli”, Via Pansini, 5, Naples, 80131, ItalyTel +39335415093Fax +39 069 762 5822Email g.argenziano@gmail.comLuca BianchiUniversity of Rome “Tor Vergata”, Policlinico Tor Vergata, Viale Oxford 81, Rome, 00133, ItalyTel +39 0620902739Fax +39 0620902742Email luca.bianchi@uniroma2.itPurpose: For patients with psoriasis, treatment adherence and persistence are fundamental if therapeutic goals are to be met. Patient Support Programs (PSPs) may be used as a support tool to assist patients and health care professionals optimize treatment and improve disease management.Patients and Methods: In Italy, the PSP PSOLife CARE, which began on the 9th of February 2017 and is ongoing, aimed to support patients with psoriasis under therapy with secukinumab (Cosentyx®). A team of medical professionals including Dermatologists, Psychologists, Nutritionists, and field Nurses provided outpatient treatment as well as remote support via phone calls. Patients had a standard duration in the Program of 6 months. This report analyzes the data of patients who benefited from the Program from February 2017 to August 2020, for a total observation of 42 months.Results: We provide here a descriptive report on the benefits of participation in the PSOLife CARE Program for patients with psoriasis and medical professionals involved in their care. Throughout their time in the PSOLife CARE Program, patient satisfaction remained consistently high with sustained improvements observed in all aspects of quality of life (ie emotional, social, physical, and economic). Despite exiting from the Program, most patients continued to adhere to secukinumab. Medical professionals also reported positive outcomes on their interactions with patients, with more than half of those surveyed rating the overall quality of the Program as “Outstanding”.Conclusion: By supporting treatment adherence, the PSOLife CARE Program may have empowered patients to better manage their psoriasis, increasing their satisfaction with treatment and quality of life.Keywords: dermatology, PSOLife CARE Program, quality of life, treatment adherence |
| format |
article |
| author |
Argenziano G Amerio P Aragone MG Baggini G Baldari M Castelli G Coppola S Costanzo A De Pasquale R Fargnoli MC Foti C Giofrè C Lembo S Leporati C Loconsole F Malara G Peris K Richetta AG Savoia P Tiberio R Travaglini M Uzzauto MT Bianchi L |
| author_facet |
Argenziano G Amerio P Aragone MG Baggini G Baldari M Castelli G Coppola S Costanzo A De Pasquale R Fargnoli MC Foti C Giofrè C Lembo S Leporati C Loconsole F Malara G Peris K Richetta AG Savoia P Tiberio R Travaglini M Uzzauto MT Bianchi L |
| author_sort |
Argenziano G |
| title |
Assessing the Beneficial Impact of a Patient Support Program in Secukinumab-Treated Patients with Psoriasis in Italy |
| title_short |
Assessing the Beneficial Impact of a Patient Support Program in Secukinumab-Treated Patients with Psoriasis in Italy |
| title_full |
Assessing the Beneficial Impact of a Patient Support Program in Secukinumab-Treated Patients with Psoriasis in Italy |
| title_fullStr |
Assessing the Beneficial Impact of a Patient Support Program in Secukinumab-Treated Patients with Psoriasis in Italy |
| title_full_unstemmed |
Assessing the Beneficial Impact of a Patient Support Program in Secukinumab-Treated Patients with Psoriasis in Italy |
| title_sort |
assessing the beneficial impact of a patient support program in secukinumab-treated patients with psoriasis in italy |
| publisher |
Dove Medical Press |
| publishDate |
2021 |
| url |
https://doaj.org/article/c4a24d587ebb4a109ffacd9b7187f80d |
| work_keys_str_mv |
AT argenzianog assessingthebeneficialimpactofapatientsupportprograminsecukinumabtreatedpatientswithpsoriasisinitaly AT ameriop assessingthebeneficialimpactofapatientsupportprograminsecukinumabtreatedpatientswithpsoriasisinitaly AT aragonemg assessingthebeneficialimpactofapatientsupportprograminsecukinumabtreatedpatientswithpsoriasisinitaly AT bagginig assessingthebeneficialimpactofapatientsupportprograminsecukinumabtreatedpatientswithpsoriasisinitaly AT baldarim assessingthebeneficialimpactofapatientsupportprograminsecukinumabtreatedpatientswithpsoriasisinitaly AT castellig assessingthebeneficialimpactofapatientsupportprograminsecukinumabtreatedpatientswithpsoriasisinitaly AT coppolas assessingthebeneficialimpactofapatientsupportprograminsecukinumabtreatedpatientswithpsoriasisinitaly AT costanzoa assessingthebeneficialimpactofapatientsupportprograminsecukinumabtreatedpatientswithpsoriasisinitaly AT depasqualer assessingthebeneficialimpactofapatientsupportprograminsecukinumabtreatedpatientswithpsoriasisinitaly AT fargnolimc assessingthebeneficialimpactofapatientsupportprograminsecukinumabtreatedpatientswithpsoriasisinitaly AT fotic assessingthebeneficialimpactofapatientsupportprograminsecukinumabtreatedpatientswithpsoriasisinitaly AT giofrec assessingthebeneficialimpactofapatientsupportprograminsecukinumabtreatedpatientswithpsoriasisinitaly AT lembos assessingthebeneficialimpactofapatientsupportprograminsecukinumabtreatedpatientswithpsoriasisinitaly AT leporatic assessingthebeneficialimpactofapatientsupportprograminsecukinumabtreatedpatientswithpsoriasisinitaly AT loconsolef assessingthebeneficialimpactofapatientsupportprograminsecukinumabtreatedpatientswithpsoriasisinitaly AT malarag assessingthebeneficialimpactofapatientsupportprograminsecukinumabtreatedpatientswithpsoriasisinitaly AT perisk assessingthebeneficialimpactofapatientsupportprograminsecukinumabtreatedpatientswithpsoriasisinitaly AT richettaag assessingthebeneficialimpactofapatientsupportprograminsecukinumabtreatedpatientswithpsoriasisinitaly AT savoiap assessingthebeneficialimpactofapatientsupportprograminsecukinumabtreatedpatientswithpsoriasisinitaly AT tiberior assessingthebeneficialimpactofapatientsupportprograminsecukinumabtreatedpatientswithpsoriasisinitaly AT travaglinim assessingthebeneficialimpactofapatientsupportprograminsecukinumabtreatedpatientswithpsoriasisinitaly AT uzzautomt assessingthebeneficialimpactofapatientsupportprograminsecukinumabtreatedpatientswithpsoriasisinitaly AT bianchil assessingthebeneficialimpactofapatientsupportprograminsecukinumabtreatedpatientswithpsoriasisinitaly |
| _version_ |
1718418726376701952 |
| spelling |
oai:doaj.org-article:c4a24d587ebb4a109ffacd9b7187f80d2021-11-21T19:08:50ZAssessing the Beneficial Impact of a Patient Support Program in Secukinumab-Treated Patients with Psoriasis in Italy1177-889Xhttps://doaj.org/article/c4a24d587ebb4a109ffacd9b7187f80d2021-11-01T00:00:00Zhttps://www.dovepress.com/assessing-the-beneficial-impact-of-a-patient-support-program-in-secuki-peer-reviewed-fulltext-article-PPAhttps://doaj.org/toc/1177-889XGiuseppe Argenziano,1,* Paolo Amerio,2 Maria Grazia Aragone,3 Ginevra Baggini,4 Manuela Baldari,5 Gianpiero Castelli,6 Simmaco Coppola,7 Antonio Costanzo,8,9 Rocco De Pasquale,10 Maria Concetta Fargnoli,11 Caterina Foti,12 Claudia Giofrè,13 Serena Lembo,14 Claudia Leporati,15,16 Francesco Loconsole,17 Giovanna Malara,18 Ketty Peris,19,20 Antonio Giovanni Richetta,21 Paola Savoia,22 Rossana Tiberio,23 Massimo Travaglini,24 Maria Teresa Uzzauto,25 Luca Bianchi26,* 1Dermatology Unit, University of Campania, Naples, Italy; 2Department of Medicine and Aging Science and Dermatologic Clinic, University “G. d’Annunzio”, Chieti-Pescara, Chieti, Italy; 3ASL AL, Alessandria, Italy; 4Osp. Civile di Varzi, Pavia, Italy; 5ASL4 Liguria, Genova, Italy; 6UOSD of Dermatology, Ospedale Umberto I°, Siracusa, Italy; 7IQVIA, Rome, Italy; 8Department of Biomedical Sciences, Humanitas University, Milano, Italy; 9Skin Pathology Laboratory, Humanitas Research Hospital IRCCS, Milano, Italy; 10UOC Dermatologia, AOU Policlinico “G. Rodolico – San Marco”, Catania, Italy; 11Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy; 12Department of Biomedical Science and Human Oncology, Dermatological Clinic, University of Bari, Bari, Italy; 13U.O.C. Dermatologia, A.O. Papardo, Messina, Italy; 14Dipartimento di Medicina, Chirurgia e Odontoiatria Scuola Medica Salernitana, University of Salerno, Fisciano, Italy; 15Dermatology Unit, ASL AL Casale Monferrato, Alessandria, Italy; 16Dermatology Unit, ASL TO4 Ivrea, Torino, Italy; 17Department of Dermatology, University of Bari, Bari, Italy; 18UOC of Dermatology, Grande Ospedale Metropolitano “BMM”, Reggio Calabria, Italy; 19Institute of Dermatology, Catholic University, Rome, Italy; 20Dermatology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; 21Dipartimento di Scienze Cliniche Internistiche e Cardiovascolari Policlinico Umberto I University of Rome “La Sapienza”, Rome, Italy; 22Department of Health Science, Università del Piemonte Orientale, Novara, Italy; 23SCDU Dermatologia, AOU Maggiore della Carità, Novara, Italy; 24U.O.S.D. dermatologica - centro per la cura della psoriasi, Ospedale Perrino, Brindisi, Italy; 25U.O.C. Dermatologia, ASL Salerno, Ospedale “A:Tortora”-Pagani, Salerno, Italy; 26Dermatology Unit, Tor Vergata University Hospital, Rome, Italy*These authors contributed equally to this workCorrespondence: Giuseppe ArgenzianoDermatology Unit, University of Campania “Luigi Vanvitelli”, Via Pansini, 5, Naples, 80131, ItalyTel +39335415093Fax +39 069 762 5822Email g.argenziano@gmail.comLuca BianchiUniversity of Rome “Tor Vergata”, Policlinico Tor Vergata, Viale Oxford 81, Rome, 00133, ItalyTel +39 0620902739Fax +39 0620902742Email luca.bianchi@uniroma2.itPurpose: For patients with psoriasis, treatment adherence and persistence are fundamental if therapeutic goals are to be met. Patient Support Programs (PSPs) may be used as a support tool to assist patients and health care professionals optimize treatment and improve disease management.Patients and Methods: In Italy, the PSP PSOLife CARE, which began on the 9th of February 2017 and is ongoing, aimed to support patients with psoriasis under therapy with secukinumab (Cosentyx®). A team of medical professionals including Dermatologists, Psychologists, Nutritionists, and field Nurses provided outpatient treatment as well as remote support via phone calls. Patients had a standard duration in the Program of 6 months. This report analyzes the data of patients who benefited from the Program from February 2017 to August 2020, for a total observation of 42 months.Results: We provide here a descriptive report on the benefits of participation in the PSOLife CARE Program for patients with psoriasis and medical professionals involved in their care. Throughout their time in the PSOLife CARE Program, patient satisfaction remained consistently high with sustained improvements observed in all aspects of quality of life (ie emotional, social, physical, and economic). Despite exiting from the Program, most patients continued to adhere to secukinumab. Medical professionals also reported positive outcomes on their interactions with patients, with more than half of those surveyed rating the overall quality of the Program as “Outstanding”.Conclusion: By supporting treatment adherence, the PSOLife CARE Program may have empowered patients to better manage their psoriasis, increasing their satisfaction with treatment and quality of life.Keywords: dermatology, PSOLife CARE Program, quality of life, treatment adherenceArgenziano GAmerio PAragone MGBaggini GBaldari MCastelli GCoppola SCostanzo ADe Pasquale RFargnoli MCFoti CGiofrè CLembo SLeporati CLoconsole FMalara GPeris KRichetta AGSavoia PTiberio RTravaglini MUzzauto MTBianchi LDove Medical Pressarticledermatologypsolife care programquality of lifetreatment adherenceMedicine (General)R5-920ENPatient Preference and Adherence, Vol Volume 15, Pp 2551-2562 (2021) |